A New Way of
Diabetes Management

GluCare.Health patients are getting results, Fast.

We follow a clinical outcome based approach
& transparently report clinical results.

Book Appointment

GluCare.Health has reduced many other risks closely associated with Diabetes
in as little as 90 days.

%

⇩ Inflammation

%

⇩ Cholestrol LDL

%

⇧ Cholestrol HDL

%

⇩ Liver Function

%

⇩ Body Weight

%

⇩ Cardiovascular

Over 2.1% reduction in HbA1c in just 90 days.

GluCare.Health patients have vastly better outcomes (in just 90 days) across a range of cardiometabolic parameters. Meanwhile patients receiving usual or traditional care saw no improvement or worsening of their condition with time.

RESULTS

Glucare
90 DAYS

Usual Care
90 DAYS

Usual Care
365 DAYS

HbA1c ⇩

- 2.14%

0.05%

+ 0.20%

CVD Risk ⇩

- 39.03%

-

-

BMI ⇩

- 4.49%

-

-

Body Weight ⇩

- 4.49%

0

0

Waist Circumference ⇩

- 5.15%

-

-

Triglycerides ⇩

- 18.52%

2.50%

+ 10%

LDL ⇩

- 17.25%

- 2.75%

+ 11%

HDL ⇧

+ 5.19%

- 0.75%

- 3%

ATL ⇩

- 9.44%

- 0.50%

- 2%

Uric Acid ⇩

- 20.40%

- 1%

- 4%

hsCRP ⇩

- 6.19%

3.75%

+ 15%

GluCare 90-Day Outcomes where signicantly different from baseline (p<0.05) for HbA1c, CV Risk, BMI, Body Weight, Wast Circumference, Triglycerides, LDL, Uric Acid.
For full details: Caccelli et al, Diabetes Manag (2021) 11(9), 290-296, Usual Care DOI: 10.1107/s 13300-018-0373-9

Remote continuous data monitoring and personalized data-driven approach for managing diabetes in a virtual and physical setting

Research Article | Diabetes Management

Many factors have contributed to the global increase of Diabetes Mellitus (DM) and metabolic disorders worldwide. In the United Arab Emirates (UAE), the International rapid urbanization & socioeconomic development has led to an increased prevalence of diabetes, reaching 16.3%.

Continue Reading

ATTD (International Conference on Advanced Technologies & Treatments for Diabetes)
2022

Implementation of Remote Continuous Data Monitoring within a Clinical Setting for the Management of Type 2 Diabetes Mellitus
2022

Effectiveness of using Semaglutide combined with GluCare Health Hybrid Care Model for Weight Loss Management
2022

GluCare.Health reduces the need for prescription medication

Percentage Reduction Over 12 Months

100% on Insulin Medication

\

↓ Down to 60% usage in 3 Months

\

↓ Down to 43% usage in 6 Months

\

↓ Down to 18% usage in 9 Months

\

↓ Down to 4% usage in 12 Months

\

100% on Metformin Medication

\

↓ Down to 51% usage in 3 Months

\

↓ Down to 26% usage in 6 Months

\

↓ Down to 14% usage in 9 - 12 Months

\

100% on DPP4 Medication

\

↓ Down to 23% usage in 3 Months

\

↓ Down to 8% usage in 6 Months

\

100% Reduction in 9 Months

\

↓ Down to 54% usage in 3 Months

\

100% on SGLT2 Medication

\

↓ Down to 18% usage in 6 Months

\

↓ Down to 12% usage in 9 Months

\

↓ Down to 12% usage in 6 Months

\

↓ Down to 6% usage in 12 Months

\

100% on Sulfonyerea Medication

\

↓ Down to 19% usage in 3 Months

\

100% Reduction in 9 Months

\

What a reduction of 1% in HbA1c means
for other complications

%

⇩ End-Point Disease Related to Diabtes

%

⇩ Death Related to Diabetes

%

⇩ Heart Attack

%

⇩ Microvascular Complication

%

⇩ End-Point Disease Related to Diabtes

%

⇩ Death Related to Diabetes

%

⇩ Heart Attack

%

⇩ Microvascular Complication

Association of Glycaemia with microcvascular complications of type 2 diabetes (UKPDS 35): prospective observation study.

Association of Glycaemia with microcvascular complications of type 2 diabetes (UKPDS 35): prospective observation study.

Weight loss programme that is home delivered, made to suit your needsView
+